Further work is needed to establish whether MPZL3 acts directly as a CAM, as it contains an IgV domain, or if it alters adhesion indirectly in epithelial cells, and how MPZL3 loss drives an EMT phenotype in cancer cells. This evidence concerns the gene MPZL3 and cancer.